WallStSmart

Coincheck Group N.V. Ordinary Shares (CNCK)vsNomura Holdings Inc ADR (NMR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Nomura Holdings Inc ADR generates 357% more annual revenue ($2.33T vs $510.59B). NMR leads profitability with a 17.3% profit margin vs -0.3%. NMR earns a higher WallStSmart Score of 84/100 (A-).

CNCK

Hold

38

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 5.5
Piotroski: 3/9Altman Z: 3.81

NMR

Exceptional Buy

84

out of 100

Grade: A-

Growth: 10.0Profit: 7.0Value: 7.0Quality: 3.0
Piotroski: 4/9Altman Z: 0.53

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CNCK3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
36.1%10/10

Revenue surging 36.1% year-over-year

Altman Z-ScoreHealth
3.8110/10

Safe zone — low bankruptcy risk

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

NMR6 strengths · Avg: 9.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Operating MarginProfitability
30.8%10/10

Strong operational efficiency at 30.8%

Revenue GrowthGrowth
31.2%10/10

Revenue surging 31.2% year-over-year

PEG RatioValuation
0.828/10

Growing faster than its price suggests

P/E RatioValuation
12.8x8/10

Attractively priced relative to earnings

EPS GrowthGrowth
42.0%8/10

Earnings expanding 42.0% YoY

Areas to Watch

CNCK4 concerns · Avg: 2.8/10
Market CapQuality
$367.72M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.053/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-5.3%2/10

ROE of -5.3% — below average capital efficiency

NMR2 concerns · Avg: 1.5/10
Altman Z-ScoreHealth
0.532/10

Distress zone — elevated risk

Debt/EquityHealth
9.181/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : CNCK

The strongest argument for CNCK centers on Revenue Growth, Altman Z-Score, Price/Book. Revenue growth of 36.1% demonstrates continued momentum.

Bull Case : NMR

The strongest argument for NMR centers on Price/Book, Operating Margin, Revenue Growth. Profitability is solid with margins at 17.3% and operating margin at 30.8%. Revenue growth of 31.2% demonstrates continued momentum.

Bear Case : CNCK

The primary concerns for CNCK are Market Cap, Debt/Equity, Piotroski F-Score.

Bear Case : NMR

The primary concerns for NMR are Altman Z-Score, Debt/Equity. Debt-to-equity of 9.18 is elevated, increasing financial risk.

Key Dynamics to Monitor

CNCK profiles as a hypergrowth stock while NMR is a growth play — different risk/reward profiles.

NMR carries more volatility with a beta of 0.61 — expect wider price swings.

CNCK is growing revenue faster at 36.1% — sustainability is the question.

Monitor CAPITAL MARKETS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NMR scores higher overall (84/100 vs 38/100), backed by strong 17.3% margins and 31.2% revenue growth. Both earn "Exceptional Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Coincheck Group N.V. Ordinary Shares

FINANCIAL SERVICES · CAPITAL MARKETS · USA

Coincheck Group N.V. provides cryptocurrency exchange platform in Japan. The company is headquartered in Amsterdam, the Netherlands.

Nomura Holdings Inc ADR

FINANCIAL SERVICES · CAPITAL MARKETS · USA

Nomura Holdings, Inc. provides various financial services to individuals, corporations, financial institutions, governments, and government agencies worldwide. The company is headquartered in Tokyo, Japan.

Want to dig deeper into these stocks?